|
Oct 15
|
Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting
|
|
Sep 30
|
Galectin Therapeutics to Participate in the H.C. Wainwright MASH Conference
|
|
Jul 30
|
Galectin Therapeutics Inc.'s (NASDAQ:GALT) largest shareholders are retail investors with 57% ownership, insiders own 20%
|
|
May 15
|
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
|
|
May 13
|
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Conference
|
|
Apr 9
|
Galectin Therapeutics Reports the Positive Outcome of the Fifth Data and Safety Monitoring Board Meeting for NAVIGATE Phase 2b/3 Study of Belapectin in Patients with Cirrhotic Portal Hypertension Caused by Metabolic Dysfunction-Associated SteatoHepatitis
|
|
Mar 29
|
Galectin Therapeutics Inc (GALT) Reports 2023 Financial Results and Business Developments
|
|
Mar 29
|
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
|
|
Mar 12
|
Galectin Therapeutics Expands Clinical Team with the Appointment of Khurram Jamil, M.D. as Vice President, Clinical Development
|
|
Nov 3
|
Galectin Therapeutics to Share Five Scientific Presentations at The Liver Meeting™ 2023, Hosted by the AASLD
|
|
Apr 27
|
Galectin Therapeutics to Participate in the H.C. Wainwright BioConnect Investment Conference May 2, 2023
|